Table 3.
Results of binary regression test on baseline measured parameters to predict overall survival among patients received an intense PSMA-RLT every 4 weeks
| Basal parameters | Overall survival | ||
|---|---|---|---|
| P value | Odd ratio | 95% CI | |
| Age | 0.57 | 1.02 | 0.94–1.11 |
| *PSA | 0.01 | 2.445 | 1.180–5.066 |
| ECOG score | 0.09 | 7.69 | 0.74–79.47 |
| Karnofsky score | 0.43 | 0.97 | 0.89–1.05 |
| Pretreatments: | |||
| Enzalutamide/abiraterone | 0.10 | 3.85 | 0.79–19.31 |
| Docetaxel/cabazitaxel | 0.96 | 0.97 | 0.30–3.12 |
| Xofigo® | 0.15 | 2.33 | 0.73–7.39 |
| Hb | 0.02 | 0.67 | 0.48–0.94 |
| Thrombocyte | 0.07 | 0.99 | 0.98–1.00 |
| *Leucocyte | 0.56 | 3.28 | 0.06–180.38 |
| *Creatinine | 0.047 | 0.003 | 0.00–0.92 |
| *LDH | 0.18 | 8.60 | 0.36–203.7 |
| *AP | 0.14 | 3.88 | 0.65–23.25 |
| Localizations of metastasis: | |||
| Bone only | 0.21 | 2.14 | 0.65–7.02 |
| Lymph node only | 0.19 | 0.24 | 0.03–2.04 |
| Bone + lymph node | 0.74 | 0.83 | 0.28–2.47 |
| Liver | 0.31 | 2.44 | 0.44–13.38 |
| Lung | 0.58 | 0.53 | 0.06–5.07 |
CI confident interval, PSA prostatic specific antigen, Hb hemoglobin, LDH lactate dehydrogenase, AP alkaline phosphatase; (*) data with no Gaussian distribution and log10-transformd for analysis; statistically significant results are marked in red